- Filing of 3 new CAR-Treg patent families
- Issuance of 11 Treg patents
- Signature of licensing and options agreements with leading academic institutions
Valbonne, France, December 14, 2016 – TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative, personalized cellular immunotherapies using regulatory T cells (Treg) to treat severe chronic inflammatory and autoimmune diseases, today provides an update on its intellectual property portfolio. In 2016, TxCell has filed three new patent families related to its genetically-engineered Treg platform and obtained the issuance of eleven additional Treg patents. In addition, TxCell has contractually secured existing and future Treg-related intellectual property from leading academic institutions.